When anamorelin a GH-releasing peptide that works in the same way as GHRH, alongside AGRP was investigated for its effects on cancer patients suffering from cachexia, it was demonstrated that the use of anamorelin in mice with a model of non-small cell lung cancer did not lead to tumour growth despite a rise in GH and a trend to higher IGF-1 [3]
Circulation 148 , 16061635 (2023)
Always research interactions thoroughly before combining medications
Sebaceous gland carcinoma: review of 40 cases
The article reflects information available as of June 2026 - a point in time when the compounded GLP-1 telehealth market is active and competitive, FDA enforcement discretion policy on compounded semaglutide and tirzepatide is subject to ongoing regulatory guidance, and the broader clinical evidence base for GLP-1 receptor agonists continues to expand through newly published long-term follow-up studies
This doesn't mean it creates more growth hormone, but rather that it helps your body make better use of what it already has, potentially speeding up the regeneration of tissues